Search results
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript May 9, 2024 Sangamo ...
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These...
Simply Wall St. via Yahoo Finance· 4 days agoThe analysts might have been a bit too bullish on Sangamo Therapeutics, Inc. (NASDAQ:SGMO), given...
Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q...
Simply Wall St. via Yahoo Finance· 5 days agoSangamo Therapeutics (NASDAQ:SGMO) First Quarter 2024 Results Key Financial Results Revenue:...
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance· 7 days agoSangamo (SGMO) delivered earnings and revenue surprises of -22.73% and 94.35%, respectively, for the...
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into F
Guru Focus· 6 days agoSangamo Therapeutics Inc (SGMO, Financial), a leader in genomic medicine, disclosed its 8-K filing on May 9, 2024, revealing detailed insights into its ...
Sangamo: Q1 Earnings Snapshot
San Francisco Chronicle· 7 days agoBRISBANE, Calif. (AP) — BRISBANE, Calif. (AP) — Sangamo Therapeutics Inc. (SGMO) on...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days ago- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - - Development candidates selected for Neurocrine
